BioAge Labs Inc BIOA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$5.34 down $0.20, 3.61% at close Nov 6
Last close · Previous close $5.54
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$2.38Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$5.34down $0.20, 3.61%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$5.54Nov 5
- Volume683.56KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume776.42KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $4.81 to $25.96; now $5.34
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
BIOA trailed the S&P 500 in all 4 periods.
| Period | BIOA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BIOA: down 15.1% S&P 500: down 5.6% | BIOA trailed the S&P 500 by 9.5 percentage points Trailed |
| 3M | BIOA: down 52.6% S&P 500: down 4.1% | BIOA trailed the S&P 500 by 48.5 percentage points Trailed |
| YTD | BIOA: down 59.6% S&P 500: up 8.7% | BIOA trailed the S&P 500 by 68.3 percentage points Trailed |
| 1Y | BIOA: down 28.5% S&P 500: up 10.9% | BIOA trailed the S&P 500 by 39.4 percentage points Trailed |
$10,000 invested in BIOA a year ago (Nov 6, 2025) would be worth about $7,149 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
BIOA trailed the S&P 500 in all 4 periods.
| Period | BIOA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BIOA: down 15.1% S&P 500: down 5.6% | BIOA trailed the S&P 500 by 9.5 percentage points Trailed |
| 3M | BIOA: down 52.6% S&P 500: down 4.3% | BIOA trailed the S&P 500 by 48.3 percentage points Trailed |
| YTD | BIOA: down 59.6% S&P 500: up 7.8% | BIOA trailed the S&P 500 by 67.4 percentage points Trailed |
| 1Y | BIOA: down 28.5% S&P 500: up 9.7% | BIOA trailed the S&P 500 by 38.2 percentage points Trailed |
$10,000 invested in BIOA a year ago (Nov 6, 2025) would be worth about $7,149 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$25.83
Closing high on . Now 79.3% below that record.
Split-adjusted daily closes since Sep 26, 2024.
Stock splits
BIOA hasn’t split since its price history begins in 2024.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $10.36Mup 168.1%
- Net income
- −$94.46M
- Diluted EPS
- −$2.38
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$23.41M | −$6.70 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$21.13M | $15.13 |
| Q1 FY25 (Mar 31, 2025) | $1.45M | −$12.93M | −$0.36 |
| Q2 FY25 (Jun 30, 2025) | $2.41M | −$21.56M | −$0.60 |
| Q3 FY25 (Sep 30, 2025) | $2.05M | −$20.17M | −$0.56 |
| Q4 FY25 (Dec 31, 2025) | $3.08M | −$25.94M | −$0.72 |
| Q1 FY26 (Mar 31, 2026) | $2.77M | −$22.25M | −$0.52 |
| Q2 FY26 (Jun 30, 2026) | $2.45M | −$26.10M | −$0.58 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Dec 31, 2022) | $0.00 | −$39.72M | −$5.32 |
| FY23 (Dec 31, 2023) | $0.00 | −$63.85M | −$38.17 |
| FY24 (Dec 31, 2024) | $0.00 | −$71.11M | −$6.63 |
| FY25 (Dec 31, 2025) | $9.00M | −$80.61M | −$2.24 |
Margins
- Gross 100.0%
- Operating −1,026.3%
- Net −912.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$88.09MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$87.60MLast 12 months
- Capital spending$488.00KLast 12 months
- −850.7%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $160.23MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $381.36MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$2.84MAs of Jun 30, 2026
- Net cash$378.53MAs of Jun 30, 2026
- 17.19As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −29.0%Last 12 months
Over the last 12 months, BioAge Labs lost money: its net loss was 29.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −27.1%Last 12 months
Over the last 12 months, BioAge Labs’s net loss was 27.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About BioAge Labs Inc
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
BIOA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
BIOA stock FAQ
What is BIOA stock’s price today?
BioAge Labs (BIOA) traded at $5.34 at the close on , down $0.20 (3.61%) from the previous close of $5.54. Over the past 52 weeks it has traded between $4.81 and $25.96.
What is BIOA’s P/E ratio?
BIOA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$2.38).
How much revenue does BioAge Labs make?
BioAge Labs reported $10.4 million of revenue over the four quarters to , up 168.1% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $2.5 million, up 1.6% from a year earlier.
Is BioAge Labs profitable?
Not over the four quarters to . BioAge Labs reported a net loss of $94.5 million across those four quarters on $10.4 million of revenue.
What are BIOA’s earnings per share?
BIOA’s diluted earnings per share were −$2.38 over the four quarters to , compared with $7.47 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.58 per share, against −$0.60 a year earlier (how EPS works).
Does BIOA pay a dividend?
BioAge Labs hasn’t paid a dividend in the last twelve months.
What is BIOA’s 52-week high and low?
Over the past 52 weeks BIOA has traded as low as $4.81 and as high as $25.96. At $5.34 at the close on , it is 79.4% below that high and 11.0% above the low.
What is BIOA’s all-time high?
BIOA’s highest closing price was $25.83 on , adjusted for stock splits. At $5.34 at the close on , it is 79.3% below that record.
Has BIOA stock ever split?
No. BIOA hasn’t split since its price history begins in 2024.
How has BIOA stock performed?
Including dividends and measured to the close on , BIOA has returned −59.6% so far this year and −28.5% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is BioAge Labs in?
BioAge Labs is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in California, USA.
What exchange does BIOA trade on?
BioAge Labs trades on the Nasdaq under the ticker symbol BIOA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.